Pembrolizumab-induced seronegative arthritis and fasciitis in a patient with lung adenocarcinoma

Basit Öğe Kaydı
dc.authoridŞenol Kobak / 0000-0001-8270-640Xen_US
dc.authorscopusidŞenol Kobak / 12782228700
dc.authorwosidŞenol Kobak / AAO-2482-2020
dc.contributor.authorKobak, Şenol
dc.date.accessioned2020-08-30T20:01:36Z
dc.date.available2020-08-30T20:01:36Z
dc.date.issued2019
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: Immune checkpoint inhibitors (CPIs) are new promising anti-cancer drugs that block negative costimulation of T-cells leading to an enhanced anti-tumor immune response. Pembrolizumab, an a monoclonal antibody, targeting the programmed cell death protein 1 (PD-1) pathway. CPIs have been associated with a number of immune-related adverse events (AEs), including musculoskeletal and rheumatic disease. Objective: To present a case with lung adenocarcinoma treated with pembrolizumab, which developed inflammatory arthritis and fasciitis. Case Report: A 73-year-old male patient was referred to the rheumatology outpatient clinic with complaints of pain in the pretibial area, pain and swelling in both ankles joints and the right fırst metacarpophalangeal (MCP) joint. Three months ago he had diagnosed with lung adenocarcinoma and pembrolizumab was started. Locomotor system complaints were started after receiving two infusions of pembrolizumab. Physical examination revealed both ankle arthritis, mild edema in the pretibial region, tenderness in the muscles and arthritis in the right fırst MCP joint. Laboratory examinations showed mild acute phase reactants elevation. Lower extremity MRI showed diffuse edema in both gastrocnemius muscle and fascia, compatible with fasciitis. Pembrolizumab-related fasciitis and seronegative arthritis were diagnosed. Low dose corticosteroid was started and a significant regression was observed in the patient's complaints. Conclusion: Inflammatory myositis with fasciitis and inflammatory arthritis in lower extremities appears to be a new adverse effect of pembrolizumab therapy. © 2019 Bentham Science Publishers.en_US
dc.identifier.citationKobak, S. (2019). Pembrolizumab-Induced seronegative arthritis and fasciitis in a patient with lung adenocarcinoma. Current drug safety, 14(3), 225-229.en_US
dc.identifier.doi10.2174/1574886314666190528121039en_US
dc.identifier.endpage229en_US
dc.identifier.issn1574-8863en_US
dc.identifier.issue3en_US
dc.identifier.pmid31132977en_US
dc.identifier.scopus2-s2.0-85072848970en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage225en_US
dc.identifier.urihttps://doi.org/10.2174/1574886314666190528121039
dc.identifier.urihttps://hdl.handle.net/20.500.12713/311
dc.identifier.volume14en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKobak, Şenolen_US
dc.language.isoenen_US
dc.publisherBentham Science Publishersen_US
dc.relation.ispartofCurrent Drug Safetyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectArthritisen_US
dc.subjectFasciitisen_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectLung Adenocarcinomaen_US
dc.subjectPembrolizumaben_US
dc.subjectRheumatic Featureen_US
dc.titlePembrolizumab-induced seronegative arthritis and fasciitis in a patient with lung adenocarcinomaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
49s.pdf
Boyut:
5.57 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu